From the other side of the consultation, briefly.
Omega-3 index improvement on the lipid panel: often overlooked but my omega-3 index went from 3.7% to 7.7% over 10 months. I supplemented with 2g EPA+DHA daily.
This matters because omega-3s are anti-inflammatory and cardioprotective, complementing the GLP-1 benefits. Target omega-3 index is >8%. Combined with the triglyceride reduction from the medication, my lipid profile is the best it's been in decades.
LibrarianMeg said:Omega-3 index improvement on the lipid panel: often overlooked but my omega-3 index went from 3.7% to 7.7% over 10 months.
Same experience, arrived at from the opposite direction. Posting only so the count is not one.
LibrarianMeg said:Omega-3 index improvement on the lipid panel: often overlooked but my omega-3 index went from 3.7% to 7.7% over 10 months.
There is a second half to this that has not been said yet. The GIP arm is doing real work rather than padding the label. GIP receptor agonism appears to improve adipose insulin sensitivity and lipid handling, and — counter-intuitively — GIP signalling in the CNS reduces nausea rather than adding to it, which is why tolerability at high total agonism is better than the GLP-1-only comparison would predict. SURPASS-2 is the cleanest head-to-head: tirzepatide beat semaglutide 1mg at every dose tier.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Following on from LibrarianMeg — and this may be the naive question:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?